Enables the scalable production of high-purity siRNA and sgRNAs for CRISPR-based gene editing drugs.
Rationally designed to enhance mRNA translation efficiency by reducing IFIT1-mediated immune suppression.
Plasmid linearization integrated with in vitro transcription (IVT) into a single streamlined step, accelerating timelines and improving mRNA quality and batch-to-batch consistency
Proprietary purification and QC workflows deliver mRNA with >98% full-length integrity and <0.01% dsRNA, setting new benchmarks in quality.
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this...
Developing new RNA therapeutics requires years of dedicated effort. However, taking a program from the promise of preclinical models into the reality of clinical development presents the fundamental challenge of...
In recent years, dual-targeting oligonucleotide drugs have become one of the hottest fields in the global pharmaceutical industry due to their advantages of synergistic effects and avoiding combination therapy. Despite...
The rise of nucleic acid therapeutics (NATs) — including oligonucleotides such as siRNA, mRNA-based products, and CRISPR-based drugs — is transforming modern medicine. These precise and potent modalities are advancing...
Hypercholesterolemia is one of the most common chronic metabolic disorders. Its core characteristic is abnormally elevated levels of "bad cholesterol," or low-density lipoprotein cholesterol (LDL-C), which can form atherosclerotic plaques...
Introduction The widespread application of CRISPR-Cas technology in the gene editing field is driving rapid growth in the demand for sgRNA synthesis. However, the traditional SPOS (Solid-Phase Oligonucleotide Synthesis) method...
Introduction siRNA, as a type of RNA interference (RNAi) technology, has demonstrated significant value and potential in the fields of gene silencing and targeted therapy. During the development of siRNA...
Advancements in RNA therapeutics are increasing the demand for high-quality synthetic oligonucleotides including siRNA (small interfering RNA) and sgRNA (single guide RNA). While conventional solid-phase oligonucleotide synthesis (SPOS) remains the...